Acquired Necroptosis Assets (from Oncotelic)
Cancer
ClinicalActive
Key Facts
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering is a private, pre-revenue biotech firm leveraging synthetic biology to engineer immunotherapies for oncology and autoimmune conditions. The company recently expanded its pipeline through the acquisition of clinical-stage necroptosis cancer therapy assets from Oncotelic Therapeutics in April 2024. With an experienced leadership team featuring veterans from the biopharma industry, Mosaic is building a platform aimed at creating next-generation treatments. Its strategic focus combines internal platform development with asset acquisitions to accelerate progress.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |